🆕Recommendation provided by Pharmacovigilance Risk Assessment Committee (#PRAC) about Janus kinase inhibitors #JAKi
⏩EMA recommends measures to minimise risk of serious side effects with #JAKi for chronic inflammatory disorders.
https://www.ema.europa.eu/en/documents/referral/janus-kinase-inhibitors-jaki-article-20-referral-ema-recommends-measures-minimise-risk-serious-side_en.pdf
⏩EMA recommends measures to minimise risk of serious side effects with #JAKi for chronic inflammatory disorders.
